Finally, we used chemical inhibitors to TBK1 and JAK1/2 to show that RBN2397 inhibition of prostate cancer cell growth can be distinguished from the RBN2397 effect on PARP7 regulation of type I IFN signaling. The gene discussed is JAK1; the disease is prostate carcinoma.